Borga O, Borga B
J Pharmacokinet Biopharm. 1997; 25(1):63-77.
PMID: 9353694
DOI: 10.1023/a:1025719827072.
du Souich P, Verges J, Erill S
Clin Pharmacokinet. 1993; 24(6):435-40.
PMID: 8513647
DOI: 10.2165/00003088-199324060-00001.
Muret P, Humbert P, Makki S, Bechtel P, Urien S, Tillement J
Arch Dermatol Res. 1993; 285(5):287-90.
PMID: 8379689
DOI: 10.1007/BF00371598.
Trenk D, Jahnchen E
J Pharmacokinet Biopharm. 1980; 8(2):177-91.
PMID: 7431221
DOI: 10.1007/BF01065192.
Reves J, Newfield P, Smith L
Can Anaesth Soc J. 1981; 28(6):556-60.
PMID: 7306859
DOI: 10.1007/BF03007152.
Altered plasma protein binding of drugs in thyroid disease.
Feely J, Stevenson I, Crooks J
Clin Pharmacokinet. 1981; 6(4):298-305.
PMID: 7249488
DOI: 10.2165/00003088-198106040-00004.
The effect of malnutrition on the pharmacokinetics of phenylbutazone.
Krishnaswamy K, Ushasri V, Naidu N
Clin Pharmacokinet. 1981; 6(2):152-9.
PMID: 7214778
DOI: 10.2165/00003088-198106020-00005.
Serum protein binding of diazepam in maternal and foetal serum during pregnancy.
Lee J, Chen S, Richens A, Menabawey M, Chard T
Br J Clin Pharmacol. 1982; 14(4):551-4.
PMID: 7138739
PMC: 1427594.
DOI: 10.1111/j.1365-2125.1982.tb02027.x.
Plasma protein binding of drugs in pregnancy.
Perucca E, Crema A
Clin Pharmacokinet. 1982; 7(4):336-52.
PMID: 6749369
DOI: 10.2165/00003088-198207040-00004.
Pharmacokinetic effects of altered plasma protein binding of drugs in renal disease.
Keller F, Maiga M, Neumayer H, Lode H, Distler A
Eur J Drug Metab Pharmacokinet. 1984; 9(3):275-82.
PMID: 6519129
DOI: 10.1007/BF03189651.
Serum protein binding of tolbutamide in patients treated with antiepileptic drugs.
Fernandez M, Erill S, Lucena M, Pita E
Clin Pharmacokinet. 1985; 10(5):451-5.
PMID: 3930124
DOI: 10.2165/00003088-198510050-00007.
Protein binding as a primary determinant of the clinical pharmacokinetic properties of non-steroidal anti-inflammatory drugs.
Lin J, Cocchetto D, DUGGAN D
Clin Pharmacokinet. 1987; 12(6):402-32.
PMID: 3301150
DOI: 10.2165/00003088-198712060-00002.
Effects of ethanol on drug and metabolite pharmacokinetics.
Lane E, Guthrie S, Linnoila M
Clin Pharmacokinet. 1985; 10(3):228-47.
PMID: 2861929
DOI: 10.2165/00003088-198510030-00003.
Binding of a metabolite of triflusal (2-hydroxy-4-trifluoromethylbenzoic acid) to serum proteins in rat and man.
Mis R, Ramis J, Conte L, Forn J
Eur J Clin Pharmacol. 1992; 42(2):175-9.
PMID: 1618249
DOI: 10.1007/BF00278480.
Interaction of phenylbutazone with racemic phenprocoumon and its enantiomers in rats.
Schmidt W, Jahnchen E
J Pharmacokinet Biopharm. 1979; 7(6):643-63.
PMID: 529027
DOI: 10.1007/BF01061212.
The protein binding of methotrexate by the serum of normal subjects.
Steele W, Lawrence J, Stuart J, McNeill C
Eur J Clin Pharmacol. 1979; 15(5):363-6.
PMID: 456408
DOI: 10.1007/BF00558441.
Pulmonary disease and drug kinetics.
du Souich P, McLean A, Lalka D, Erill S, Gibaldi M
Clin Pharmacokinet. 1978; 3(4):257-66.
PMID: 354634
DOI: 10.2165/00003088-197803040-00001.
Protein binding of coumarin anticoagulants in disease states.
Bachmann K, Shapiro R
Clin Pharmacokinet. 1977; 2(2):110-26.
PMID: 324687
DOI: 10.2165/00003088-197702020-00003.
